Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection
Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Journal of Pharmacy and Bioallied Sciences |
Subjects: | |
Online Access: | http://www.jpbsonline.org/article.asp?issn=0975-7406;year=2013;volume=5;issue=4;spage=253;epage=256;aulast=Karlafti |